Aurora Cannabis to Host Second Quarter 2027 Investor Conference Call

EDMONTON, Alberta--(BUSINESS WIRE)--Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it will host an investor conference call on Thursday, November 12, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time to discuss its financial results for the second quarter 2027. The Company will report its financial results prior to market open that same morning. Investor Conference Call Details DA.

Business Wire • 13 hours ago

ACB's Q2 Earnings on Deck: International Medical Cannabis in Focus

Aurora Cannabis heads into Q2 earnings with revenues expected to fall 20.1%, as market exits and reimbursement cuts weigh on results while international medical cannabis markets offer support.

Zacks Investment Research • Oct 27, 2026

Aurora Cannabis Announces the Alberta Securities Commission has dismissed Curaleaf's Application and ruled in favour of the Company's At-the-Market Program

NASDAQ | TSX: ACB Alberta Securities Commission dismisses Curaleaf's application concerning Aurora's ATM program. Curaleaf's unsuccessful application before the Alberta Securities Commission confirms Aurora's ATM program is compliant with Securities laws.

PRNewsWire • Oct 26, 2026

Aurora Rejects Curaleaf's Higher Bid, But the Takeover Fight Isn't Over

Curaleaf TodayCURLFCuraleaf$7.80 +0.17 (+2.26%) As of 02:38 PM Eastern52-Week Range$5.40▼$15.15Price Target$6.00Add to WatchlistCuraleaf Holdings, Inc. OTCMKTS: CURLF is aggressively maneuvering to absorb Aurora Cannabis Inc. NASDAQ: ACB, leveraging an estimated 217% ex-cash premium to force a shareholder reckoning and bypass an entrenched board.

MarketBeat • Oct 20, 2026

Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside

NASDAQ | TSX: ACB Revised Hostile Bid continues to significantly undervalue Aurora; fails to address concerns previously raised by the Board.  Aurora's Special Committee is actively exploring strategic alternatives to maximize value for Aurora shareholders.

PRNewsWire • Oct 14, 2026

Aurora Cannabis Stock Has Soared 25% Since Curaleaf First Made an Offer to Buy Its Business. Here's Why I Think It Can Go Even Higher

Curaleaf recently raised its offer for Aurora Cannabis to $5. Aurora is reviewing the bid and will make a recommendation to shareholders on what to do.

The Motley Fool • Oct 12, 2026

Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower Output

NASDAQ | TSX: ACB Multi-million-dollar investment results in increased domestic production capacity in Germany, more than doubling expected annual flower output. Enhanced facility adopts Aurora's proven cultivation practices and proprietary genetics to support consistent, high-quality production.

PRNewsWire • Oct 8, 2026

Tilray Brands Sinks 4% as Record Revenue Masks Shrinking Cannabis Sales; Canopy Growth and Aurora Cannabis Ease

A Q1 FY2027 revenue record from Tilray Brands (NASDAQ:TLRY) is drawing heavy selling, because the segment that built the company's following moved the wrong way. Tilray Brands shares are at $3.

24/7 Wall Street • Oct 8, 2026

Curaleaf's Higher Aurora Bid Raises the Stakes in Cannabis Consolidation

The multi-year cannabis sector bear market is starting to give way to a calculated wave of industry consolidation. Behind the urge to merge is a significant shift in U.S. federal regulatory policy, encouraging better-capitalized operators to secure global supply chains before tax relief drives widespread multiple expansion.

MarketBeat • Oct 6, 2026

Aurora Urges Shareholders to Take No Action to Revised Hostile Bid by Curaleaf as Formal Review Underway

Aurora's Special Committee will commence a thorough and independent review of the revised Hostile Bid and the Board will provide a formal recommendation to shareholders once the review is complete.   Shareholders are advised to TAKE NO ACTION pending a formal recommendation.

PRNewsWire • Oct 6, 2026